Alimera Sciences Inc. (ALIM)

1.02
0.04 4.42
NASDAQ : Health Technology
Prev Close 0.98
Open 0.97
Day Low/High 0.96 / 1.02
52 Wk Low/High 0.74 / 1.42
Volume 43.02K
Avg Volume 142.20K
Exchange NASDAQ
Shares Outstanding 70.04M
Market Cap 67.35M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Announces Exchange Of Series B Preferred Stock For Newly Issued Series C Preferred Stock

Alimera Sciences Announces Exchange Of Series B Preferred Stock For Newly Issued Series C Preferred Stock

ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc.

Alimera Sciences To Present At The 20th Annual HC Wainwright Global Investment Conference

Alimera Sciences To Present At The 20th Annual HC Wainwright Global Investment Conference

ATLANTA, Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive...

Alimera Sciences To Present At The Annual B. Riley Healthcare Conference

Alimera Sciences To Present At The Annual B. Riley Healthcare Conference

ATLANTA, Aug. 28, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive...

Alimera Sciences Reports Second Quarter 2018 Results

Alimera Sciences Reports Second Quarter 2018 Results

- Record Net Revenue of $10.9 Million in Q2 2018

Alimera Sciences To Report Second Quarter 2018 Results July 30, 2018

Alimera Sciences To Report Second Quarter 2018 Results July 30, 2018

ATLANTA, July 18, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended...

Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

ATLANTA, July 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that 8 presentations on ILUVIEN data have been accepted...

Alimera Sciences Appoints Mary T. Szela To Its Board Of Directors

Alimera Sciences Appoints Mary T. Szela To Its Board Of Directors

Ms. Szela brings extensive global brand experience to the Alimera Board

The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

More patients in England and Wales with chronic DME could benefit from low-dose corticosteroid intravitreal implant that lasts up to three years

Alimera Sciences Terminates At-the-Market Offering Agreement

Alimera Sciences Terminates At-the-Market Offering Agreement

ATLANTA, June 4, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank...

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

TheStreet Quant Rating: D- (Sell)